• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

掌跖红斑感觉异常与大剂量甲氨蝶呤相关：病例报告。

Palmar-plantar erythrodysesthesia associated with high-dose methotrexate: Case report.

机构信息

Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.

出版信息

Cancer Rep (Hoboken). 2020 Oct;3(5):e1270. doi: 10.1002/cnr2.1270. Epub 2020 Aug 7.

DOI:10.1002/cnr2.1270
PMID:32767666
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7941550/
Abstract

BACKGROUND

Palmar-plantar erythrodysesthesia (PPE) is a common adverse event seen with many chemotherapeutic agents as well as targeted therapies which is very debilitating for the patient. To the best of our knowledge there are only a few cases of PPE reported with methotrexate infusion to date.

CASE AND CONCLUSION

We report a case of Burkitt Lymphoma, who developed severe PPE with methotrexate infusion and responded very well with conservative management and dose reduction in subsequent cycles.

摘要

背景

手掌-足底红斑感觉异常（PPE）是许多化疗药物以及靶向治疗药物常见的不良反应，使患者非常虚弱。据我们所知，迄今为止，只有少数几例报告显示甲氨蝶呤输注会出现 PPE。

病例和结论

我们报告了一例患有伯基特淋巴瘤的患者，该患者在输注甲氨蝶呤后出现严重的 PPE，通过保守治疗和随后周期减少剂量，病情得到了很好的缓解。

相似文献

1
Palmar-plantar erythrodysesthesia associated with high-dose methotrexate: Case report.掌跖红斑感觉异常与大剂量甲氨蝶呤相关：病例报告。
Cancer Rep (Hoboken). 2020 Oct;3(5):e1270. doi: 10.1002/cnr2.1270. Epub 2020 Aug 7.
2
Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.大剂量甲氨蝶呤或大剂量阿糖胞苷治疗后出现的手足红斑性感觉异常综合征。
Cancer. 2017 Sep 15;123(18):3602-3608. doi: 10.1002/cncr.30762. Epub 2017 May 11.
3
Docetaxel induced severe palmar plantar erythrodysesthesia.多西他赛引起严重的手足红斑性感觉异常。
Pan Afr Med J. 2018 May 29;30:70. doi: 10.11604/pamj.2018.30.70.14741. eCollection 2018.
4
Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.多西他赛相关的手足红斑性感觉异常：一例病例报告及文献综述
J Oncol Pharm Pract. 2014 Feb;20(1):73-80. doi: 10.1177/1078155213475466. Epub 2013 Mar 11.
5
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).在接受聚乙二醇化脂质体阿霉素治疗的乳腺癌患者中使用止汗剂预防手足红斑性感觉异常（SAKK 92/08）
Breast. 2014 Jun;23(3):244-9. doi: 10.1016/j.breast.2014.02.005. Epub 2014 Mar 20.
6
Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.卡培他滨化疗相关的手足红斑性感觉异常：一例报告
Pan Afr Med J. 2015 Jul 30;21:228. doi: 10.11604/pamj.2015.21.228.7525. eCollection 2015.
7
Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.复发性卵巢癌患者接受多柔比星脂质体注射液致掌跖感觉丧失不良事件的临床危险因素分析。
Gynecol Oncol. 2013 Dec;131(3):683-8. doi: 10.1016/j.ygyno.2013.09.031. Epub 2013 Oct 4.
8
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.聚乙二醇化脂质体阿霉素随时间推移引起手足红斑性感觉异常的危险因素：单核细胞计数和基线临床参数评估
Cancer Chemother Pharmacol. 2015 Nov;76(5):1033-9. doi: 10.1007/s00280-015-2875-8. Epub 2015 Sep 29.
9
A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).一项关于局部应用吡哆醇对卡培他滨或聚乙二醇脂质体阿霉素（PLD）引起的手掌-足底红斑感觉异常（PPE）影响的随机双盲、安慰剂对照的初步研究。
Eur J Oncol Nurs. 2021 Feb;50:101866. doi: 10.1016/j.ejon.2020.101866. Epub 2020 Nov 11.
10
Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.脂质体阿霉素相关掌跖红斑感觉异常（手足综合征）：一例报告。
J Int Med Res. 2020 Dec;48(12):300060520974854. doi: 10.1177/0300060520974854.

引用本文的文献

1
A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy.与抗癌治疗相关的大疱性皮肤不良事件综述
Biomedicines. 2023 Jan 24;11(2):323. doi: 10.3390/biomedicines11020323.

本文引用的文献

1
Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.大剂量甲氨蝶呤或大剂量阿糖胞苷治疗后出现的手足红斑性感觉异常综合征。
Cancer. 2017 Sep 15;123(18):3602-3608. doi: 10.1002/cncr.30762. Epub 2017 May 11.
2
Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.化疗引起的手足综合征和甲改变：临床特征、病因、发病机制和治疗的综述。
J Am Acad Dermatol. 2014 Oct;71(4):787-94. doi: 10.1016/j.jaad.2014.03.019. Epub 2014 May 1.
3
Probable cytarabine-induced acral erythema: report of 2 pediatric cases.可能由阿糖胞苷引起的手足红斑：2例儿科病例报告
J Pediatr Hematol Oncol. 2013 Jan;35(1):e11-3. doi: 10.1097/MPH.0b013e3182580ba0.
4
[6-mercaptopurine-related hand-foot syndrome in a four-year-old child].
Ann Dermatol Venereol. 2008 Aug-Sep;135(8-9):580-3. doi: 10.1016/j.annder.2008.02.021. Epub 2008 May 27.
5
[Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases].[化疗引起的手足红斑：44例临床及组织病理学研究]
Actas Dermosifiliogr. 2008 May;99(4):281-90.
6
Candidate mechanisms for capecitabine-related hand-foot syndrome.卡培他滨相关手足综合征的潜在机制。
Br J Clin Pharmacol. 2008 Jul;66(1):88-95. doi: 10.1111/j.1365-2125.2008.03159.x. Epub 2008 Mar 13.
7
Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.手足红斑性感觉异常（PPE）：一项文献综述及对癌症中心经验的评论
Eur J Oncol Nurs. 2007 Jul;11(3):238-46. doi: 10.1016/j.ejon.2006.10.004. Epub 2007 Mar 9.
8
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.认识手足综合征。评估卡培他滨的临床试验见解。
Oncology (Williston Park). 2004 Aug;18(9):1161-8, 1173; discussion 1173-6, 1181-4.
9
Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.抗肿瘤治疗引起的手足红斑感觉异常综合征（“手足”综合征）。发病率、识别与管理。
Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34. doi: 10.2165/00128071-200001040-00004.